Arvinas ARVN
NASDAQ ARVN
$9.34 +0.03 (+0.32%)
As of: Sep 4, 2026 · 12:51 PM EDT

Arvinas (ARVN) Consolidated Net Income (2017 - 2026)

Arvinas (ARVN) posted quarterly Consolidated Net Income of -$57.6 million for Q1 2026, down 169.48% year-over-year from $82.9 million in Q1 2025, and up 14.54% quarter-over-quarter from -$67.4 million in Q4 2025.

Analysis

Arvinas (ARVN) Consolidated Net Income (2017 - 2026) Analysis & Trends

Arvinas' Consolidated Net Income history runs 10 years deep, the most recent figure standing at -$57.6 million for Q1 2026.

  • In Q1 2026, Consolidated Net Income fell 169.48% year-over-year to -$57.6 million; the TTM figure through Mar 2026 stood at -$221.3 million (down 374.89% YoY), while the FY2025 annual figure was -$80.8 million, up 59.38% from the prior year.
  • Consolidated Net Income for Q1 2026 stood at -$57.6 million, up from -$67.4 million in the prior quarter.
  • The five-year high for Consolidated Net Income was $82.9 million in Q1 2025, with the low at -$154.8 million in Q4 2023.
  • The 5-year median for Consolidated Net Income is -$63.3 million (2022), against an average of -$57.3 million.
  • The sharpest annual moves came in 2025 and 2026: Consolidated Net Income surged 219.45% in 2025, then plunged 169.48% in 2026.
  • Arvinas' Consolidated Net Income stood at -$80.1 million in 2022, then tumbled by 93.26% to -$154.8 million in 2023, then soared by 70.87% to -$45.1 million in 2024, then sank by 49.45% to -$67.4 million in 2025, then gained by 14.54% to -$57.6 million in 2026.
  • Business Quant data shows ARVN's Consolidated Net Income at -$57.6 million in Q1 2026, -$67.4 million in Q4 2025, and -$35.1 million in Q3 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Consol Net Inc. (Qtr)
1 Vertex Pharmaceuticals 139.62 Bn 131.77 Bn 2.84 Bn 1.10 Bn
2 Regeneron Pharmaceuticals 85.73 Bn 77.73 Bn 3.93 Bn 1.30 Bn
3 Argenx Se 63.53 Bn 58.35 Bn 1.37 Bn 601.00 Mn
4 Moderna 58.23 Bn 53.09 Bn 52.00 Mn -782.00 Mn
5 Revolution Medicines 44.05 Bn 44.05 Bn - -644.37 Mn
6 BeOne Medicines 40.03 Bn 34.93 Bn 1.53 Bn 237.01 Mn
7 Alnylam Pharmaceuticals 35.50 Bn 32.19 Bn 992.69 Mn 164.49 Mn
8 Royalty Pharma 28.52 Bn 27.68 Bn - 81.49 Mn
9 Insmed 27.46 Bn 26.30 Bn 358.27 Mn -13.27 Mn
10 Arvinas 604.91 Mn 37.01 Mn - 169.40 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 169.40 Mn
Mar 31, 2026 -57.60 Mn
Dec 31, 2025 -67.40 Mn
Sep 30, 2025 -35.10 Mn
Jun 30, 2025 -61.20 Mn
Mar 31, 2025 82.90 Mn
Dec 31, 2024 -45.10 Mn
Sep 30, 2024 -49.20 Mn
Jun 30, 2024 -35.20 Mn
Mar 31, 2024 -69.40 Mn
Dec 31, 2023 -154.80 Mn
Sep 30, 2023 -63.90 Mn
Jun 30, 2023 -65.30 Mn
Mar 31, 2023 -80.80 Mn
Dec 31, 2022 -80.10 Mn
Sep 30, 2022 -63.30 Mn
Jun 30, 2022 -67.50 Mn
Mar 31, 2022 -61.10 Mn
Dec 31, 2021 -46.10 Mn
Sep 30, 2021 -46.80 Mn